

Table SI. Association between OTUD isoforms and tumor stages in patients with NSCLC.

Gene	Stages	Expression groups		HR (95% CI)	P-value
		Low	High		
OTUD1	I	112	112	1.34 (0.9-1.98)	0.140
	II	96	94	0.63 (0.43-0.92)	0.016
	III	14	15	0.41 (0.17-1.0)	0.043
	IV	12	11	0.72 (0.31-0.67)	0.440
OTUD2	I	218	218	1.02 (0.77-1.36)	0.870
	II	299	290	1.0 (0.8-1.25)	0.970
	III	41	40	0.89 (0.55-1.47)	0.660
	IV	23	23	0.66 (0.35-1.23)	0.190
OTUD3	I	218	219	0.85 (0.64-1.13)	0.250
	II	295	294	0.84 (0.67-1.04)	0.110
	III	41	40	1.01 (0.62-1.66)	0.950
	IV	23	23	0.67 (0.35-1.27)	0.220
OTUD4	I	219	218	0.92 (0.69-1.22)	0.570
	II	294	295	1.14 (0.92-1.43)	0.240
	III	40	41	0.77 (0.47-1.26)	0.290
	IV	23	23	0.76 (0.41-1.41)	0.380
OTUD5	I	113	111	0.81 (0.55-1.21)	0.310
	II	95	95	0.71 (0.49-1.03)	0.073
	III	14	15	1.11 (0.5-2.44)	0.800
	IV	12	11	0.84 (0.36-1.96)	0.690
OTUD6B	I	113	111	1.31 (0.88-1.96)	0.180
	II	95	95	1.44 (0.98-2.13)	0.065
	III	14	15	1.44 (0.64-3.23)	0.380
	IV	12	11	2.17 (0.9-5.26)	0.080
ALG13	I	218	219	0.91 (0.68-1.2)	0.500
	II	294	295	1.13 (0.91-1.42)	0.260
	III	40	41	1.11 (0.68-1.82)	0.670
	IV	23	23	0.84 (0.45-1.57)	0.580

OTUD, OTU domain-containing proteins; ALG13, putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval.

Table SII. Association between OTUD isoforms and lymph node status in patients with NSCLC.

Gene	Lymph node status	Expression groups		HR (95% CI)	P-value
		Low	High		
OTUD1	0	162	162	0.98 (0.72-1.33)	0.880
	1	51	51	0.84 (0.52-1.38)	0.490
	2	17	15	0.36 (0.17-0.79)	0.008
OTUD2	0	394	387	1.05 (0.85-1.3)	0.630
	1	126	126	1.02 (0.74-1.39)	0.920
	2	56	56	0.85 (0.57-1.27)	0.430
OTUD3	0	391	390	0.96 (0.78-1.18)	0.680
	1	126	126	0.92 (0.67-1.26)	0.610
	2	56	56	0.89 (0.6-1.34)	0.590
OTUD4	0	390	391	0.92 (0.75-1.14)	0.460
	1	126	126	0.95 (0.7-1.3)	0.760
	2	56	55	1.19 (0.79-1.8)	0.400
OTUD5	0	163	161	0.8 (0.59-1.1)	0.170
	1	51	51	0.95 (0.57-1.56)	0.830
	2	16	16	0.48 (0.23-1.03)	0.055
OTUD6B	0	163	161	1.16 (0.84-1.6)	0.360
	1	51	51	2.29 (1.37-3.83)	0.001
	2	16	16	1.14 (0.54-2.4)	0.740
ALG13	0	392	389	0.99 (0.81-1.22)	0.950
	1	126	126	0.71 (0.52-0.97)	0.001
	2	56	55	0.95 (0.63-1.42)	0.800

OTUD, OTU domain-containing proteins; ALG13, putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval.

Table SIII. Association between OTUD isoforms and smoking status in patients with NSCLC.

Gene	Smoking status	Expression groups		HR (95% CI)	P-value
		Low	High		
OTUD1	Never smoked	151	149	0.55 (0.36-0.84)	0.005
	Smoked	70	71	0.33 (0.14-0.8)	0.009
OTUD2	Never smoked	411	409	1.41 (1.14-1.74)	0.001
	Smoked	103	102	1.84 (1.03-3.28)	0.037
OTUD3	Never smoked	412	408	1.06 (0.87-1.31)	0.560
	Smoked	102	103	0.99 (0.57-1.72)	0.960
OTUD4	Never smoked	411	409	0.86 (0.7-1.05)	0.140
	Smoked	102	103	0.45 (0.25-0.81)	0.006
OTUD5	Never smoked	150	150	1.36 (0.9-2.04)	0.140
	Smoked	70	71	0.64 (0.28-1.45)	0.280
OTUD6B	Never smoked	150	150	0.79 (0.52-1.19)	0.250
	Smoked	70	71	0.37 (0.15-0.88)	0.020
ALG13	Never smoked	410	410	0.88 (0.72-1.08)	0.230
	Smoked	102	103	0.55 (0.31-0.97)	0.036

OTUD, OTU domain-containing proteins; ALG13, putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval.

Table SIV. Association between OTUD isoforms and sex in patients with NSCLC.

Gene	Sex	Expression groups		HR (95% CI)	P-value
		Low	High		
OTUD1	Female	188	187	0.52 (0.37-0.74)	<0.001
	Male	330	329	0.69 (0.56-0.84)	<0.001
OTUD2	Female	358	357	1.51 (1.19-1.91)	<0.001
	Male	556	544	1.09 (0.93-1.28)	0.280
OTUD3	Female	360	355	0.99 (0.78-1.24)	0.920
	Male	555	545	0.82 (0.7-0.96)	0.014
OTUD4	Female	358	357	0.86 (0.68-1.08)	0.190
	Male	551	549	0.76 (0.65-0.89)	<0.001
OTUD5	Female	189	186	0.86 (0.61-1.2)	0.360
	Male	330	329	0.85 (0.7-1.05)	0.130
OTUD6B	Female	188	187	0.99 (0.71-1.39)	0.960
	Male	332	327	1.22 (1.0-1.49)	0.053
ALG13	Female	358	357	0.78 (0.62-0.98)	0.034
	Male	550	550	0.75 (0.64-0.88)	0.00037

OTUD, OTU domain-containing proteins; ALG13, putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval.

Table SV. Association between OTUD isoforms and chemotherapy in patients with NSCLC.

Gene	Chemotherapy	Expression groups		HR (95% CI)	P-value
		Low	High		
OTUD1	No	10	11	4.45 (0.52-38.14)	0.140
	Yes	18	16	0.91 (0.28-2.9)	0.870
OTUD2	No	157	153	0.77 (0.35-1.07)	0.120
	Yes	88	88	0.99 (0.66-1.49)	0.970
OTUD3	No	155	155	1.09 (0.78-1.52)	0.620
	Yes	88	88	0.57 (0.38-0.86)	0.007
OTUD4	No	155	155	1.16 (0.83-1.63)	0.380
	Yes	88	88	0.67 (0.44-1.0)	0.051
OTUD5	No	10	11	0.6 (0.11-3.29)	0.350
	Yes	17	17	0.57 (0.18-1.84)	0.340
OTUD6B	No	10	11	3.11 (0.36-26.82)	0.280
	Yes	17	17	1.59 (0.5-5.08)	0.430
ALG13	No	155	155	0.86 (0.61-1.2)	0.380
	Yes	88	88	0.76 (0.5-1.15)	0.200

OTUD, OTU domain-containing proteins; ALG13, putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval.